$RDZN Balance Sheet | Understand Stock

$RDZN

$1.12 -$0.01 (0.88%) Close

$RDZN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q1 FY2027 As of Jun 30, 2026	Q4 FY2026 As of Mar 31, 2026	Q3 FY2026 As of Dec 31, 2025	Q2 FY2026 As of Sep 30, 2025	Q1 FY2026 As of Jun 30, 2025	Q4 FY2025 As of Mar 31, 2025	Q3 FY2025 As of Dec 31, 2024	Q2 FY2025 As of Sep 30, 2024	Q1 FY2025 As of Jun 30, 2024	Q4 FY2024 As of Mar 31, 2024	Q3 FY2024 As of Dec 31, 2023	Q2 FY2024 As of Sep 30, 2023	Q1 FY2024 As of Jun 30, 2023	Q4 FY2023 As of Mar 31, 2023	Q3 FY2023 As of Dec 31, 2022	Q2 FY2023 As of Sep 30, 2022	Q1 FY2023 As of Jun 30, 2022	Q4 FY2022 As of Mar 31, 2022
Assets
Current assets:
Cash
Prepaid expenses
Due from Sponsor
Cash and cash equivalents
Accounts receivable, net
Inventories
Prepayments and other current assets
Investments
Total current assets

Prepaid expenses
Investments held in Trust Account
Non current assets
Restricted cash
Non marketable securities
Property and equipment, net
Goodwill
Operating lease right-of-use assets
Intangible assets, net
Other long-term assets
Total Non current assets
Total assets
Current liabilities
Accrued offering costs
Convertible Note – related party
Accrued expenses
Extension Note – related party, net of discount of $113,004
Convertible Note—related party
Current portion of long-term borrowings
Short-term borrowings
Due to insurer
Accounts payable and accrued expenses
Derivative warrant liabilities
Short-term operating lease liabilities
Other current liabilities
Total current liabilities

Deferred underwriting fee
Long-term borrowings
Long-term operating lease liabilities
Other long-term liabilities
Total Non current liabilities
Total liabilities
None authorized or issued as of March 31, 2024; Series A and A1 preferred stock and additional paid in capital, $0.0001 par value per share, 81,635,738 shares authorized (Series A 5,442,383 and Series A1 76,193,356); 39,868,173 shares issued and outstanding as on March 31, 2023.
Common Class A
Total none authorized or issued as of March 31, 2024; Series A and A1 preferred stock and additional paid in capital, $0.0001 par value per share, 81,635,738 shares authorized (Series A 5,442,383 and Series A1 76,193,356); 39,868,173 shares issued and outstanding as on March 31, 2023.
Shareholders’ Equity/(Deficit)
Preference shares, $0.0001 par value per share, 60,000,000 shares authorized and none issued as of March 31, 2024 and none authorized or issued as of March 31, 2023
Ordinary Shares and additional paid in capital, $0.0001 par value per share, 220,000,000 shares authorized as of June 30, 2026 and March 31, 2026; 84,598,480 and 79,695,672 shares outstanding as of June 30, 2026 and March 31, 2026, respectively
Common Class A
Common Class B
Total ordinary Shares and additional paid in capital, $0.0001 par value per share, 220,000,000 shares authorized as of June 30, 2026 and March 31, 2026; 84,598,480 and 79,695,672 shares outstanding as of June 30, 2026 and March 31, 2026, respectively

Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income/(loss)
Other components of equity
Total shareholders’ deficit

Share Application Money
Non-controlling interest
Total deficit

Total liabilities and Total Deficit

Comments